A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.
Select Content Type
Clinical Guidelines
Interests
Oncology
Obstetrics & Gynecology
Speciality
Obstetrics & Gynecology
Oncology
Book Detail
volume
478
ISSN
1432-2307
Publication Date
Actions
Download in App
Event Data
{"article_title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma.","author":"Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonz\u00e1lez-Mart\u00edn A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X","journal_title":"Virchows Archiv : an international journal of pathology","issn":"1432-2307","isbn":"","publication_date":"2021-02-01","volume":"478","issue":"2","first_page":"153","page_count":"","accession_number":"33604759","doi":"","publisher":"Springer International","doctype":"Consensus Development Conference","subjects":"Carcinoma therapy; Endometrial Neoplasms therapy; Medical Oncology standards; Biomarkers, Tumor genetics; Biopsy standards; Carcinoma genetics; Carcinoma pathology; Endometrial Neoplasms genetics; Endometrial Neoplasms pathology; Evidence-Based Medicine standards; Female; Humans; Molecular Diagnostic Techniques standards; Neoplasm Staging standards; Predictive Value of Tests; Risk Assessment; Risk Factors; Treatment Outcome","interest_area":["Oncology"," Obstetrics & Gynecology"],"abstract":"A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO\/ESTRO\/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=33604759","isPdfLink":true,"isSAML":false,"an":"33604759","number_other":"","type_pub":"","issn_electronic":"1432-2307","languages":"English","language":"eng","date_entry":"","date_update":"","titleSource":"Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Feb; Vol. 478 (2), pp. 153-190.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2021-02-01","description":"A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO\/ESTRO\/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=33604759&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonz\u00e1lez-Mart\u00edn A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X","header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"33604759","RelevancyScore":"886","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"885.599182128906"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=33604759&authtype=shib&custid=ns346513&group=main&profile=eds","physicalDescription":{"Pagination":{"StartPage":"153"}},"additionalInfo":{"Authored_By":"Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonz\u00e1lez-Mart\u00edn A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X","Journal_Info":"Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE","Publication_Type":"Consensus Development Conference; Journal Article; Practice Guideline; Systematic Review","Published_Date":"2021-02-01","Source":"Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Feb; Vol. 478 (2), pp. 153-190.","Languages":"English","Electronic_ISSN":"1432-2307","MeSH_Terms":"Carcinoma\/*therapy , Endometrial Neoplasms\/*therapy , Medical Oncology\/*standards, Biomarkers, Tumor\/genetics ; Biopsy\/standards ; Carcinoma\/genetics ; Carcinoma\/pathology ; Endometrial Neoplasms\/genetics ; Endometrial Neoplasms\/pathology ; Evidence-Based Medicine\/standards ; Female ; Humans ; Molecular Diagnostic Techniques\/standards ; Neoplasm Staging\/standards ; Predictive Value of Tests ; Risk Assessment ; Risk Factors ; Treatment Outcome","Subjects":"Biomarkers, Tumor genetics, Biopsy standards, Carcinoma genetics, Carcinoma pathology, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Evidence-Based Medicine standards, Female, Humans, Molecular Diagnostic Techniques standards, Neoplasm Staging standards, Predictive Value of Tests, Risk Assessment, Risk Factors, Treatment Outcome, Carcinoma therapy, Endometrial Neoplasms therapy, Medical Oncology standards","Title_Abbreviations":"Virchows Archiv : an international journal of pathology","Volume":"478"}}
ISSN
1432-2307
IS_Ebsco
true
Upload Link
https://search.ebscohost.com/login.aspx?direct=true&db=mdl&AN=33604759
Additional Info
["Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonz\u00e1lez-Mart\u00edn A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X","Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE","Consensus Development Conference; Journal Article; Practice Guideline; Systematic Review","2021-02-01","Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Feb; Vol. 478 (2), pp. 153-190.","English","1432-2307","Carcinoma\/*therapy , Endometrial Neoplasms\/*therapy , Medical Oncology\/*standards, Biomarkers, Tumor\/genetics ; Biopsy\/standards ; Carcinoma\/genetics ; Carcinoma\/pathology ; Endometrial Neoplasms\/genetics ; Endometrial Neoplasms\/pathology ; Evidence-Based Medicine\/standards ; Female ; Humans ; Molecular Diagnostic Techniques\/standards ; Neoplasm Staging\/standards ; Predictive Value of Tests ; Risk Assessment ; Risk Factors ; Treatment Outcome","Biomarkers, Tumor genetics, Biopsy standards, Carcinoma genetics, Carcinoma pathology, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Evidence-Based Medicine standards, Female, Humans, Molecular Diagnostic Techniques standards, Neoplasm Staging standards, Predictive Value of Tests, Risk Assessment, Risk Factors, Treatment Outcome, Carcinoma therapy, Endometrial Neoplasms therapy, Medical Oncology standards","Virchows Archiv : an international journal of pathology","478"]
Description